CLORGILINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H15Cl2NO
Molecular Weight	272.17
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(CCCOC1=C(Cl)C=C(Cl)C=C1)CC#C

InChI

InChIKey=BTFHLQRNAMSNLC-UHFFFAOYSA-N

InChI=1S/C13H15Cl2NO/c1-3-7-16(2)8-4-9-17-13-6-5-11(14)10-12(13)15/h1,5-6,10H,4,7-9H2,2H3

HIDE SMILES / InChI

Molecular Formula	C13H15Cl2NO
Molecular Weight	272.17
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB04017 | https://www.ncbi.nlm.nih.gov/pubmed/9564606 | https://www.ncbi.nlm.nih.gov/pubmed/24040395 | https://www.ncbi.nlm.nih.gov/pubmed/6342562 | https://www.ncbi.nlm.nih.gov/pubmed/20060423 | https://www.ncbi.nlm.nih.gov/pubmed/12652347

Clorgiline is a monoamine oxidase (MAO) inhibitor. Specifically, it is an irreversible and selective inhibitor of MAO-A. Clorgiline was under investigation for antidepressant and anxiolytic potential but has never been marketed, likely due to efficacy concerns. It continues to see routine use as a molecular probe in biomedical research examining a number of neurological disease and cancer models. In addition to inhibiting the MAO-A receptor, it has also been found to bind to the sigma1 receptor, and with high affinity to the I2 imidazoline receptor.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Amine oxidase [flavin-containing] A 14 Target ID: P21397 Gene ID: 4128.0 Gene Symbol: MAOA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564606	Inhibitor 8297	1.4 nM [IC50]
Sigma non-opioid intracellular receptor 1 26 Target ID: Q99720\|\|\|Q7Z653 Gene ID: 10280.0 Gene Symbol: SIGMAR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20060423	Binding Agent 1064
Nischarin 7 Target ID: Q9Y2I1\|\|\|Q9UFW3 Gene ID: 11188.0 Gene Symbol: NISCH Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12652347	Binding Agent 1064
Monoamine oxidase A 49 Target ID: CHEMBL1951 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564606 \| https://www.medchemexpress.com/Clorgiline-hydrochloride.html	Inhibitor 8297	1.4 nM [IC50]
Sigma non-opioid intracellular receptor 1 26 Target ID: Q99720\|\|\|Q7Z653 Gene ID: 10280.0 Gene Symbol: SIGMAR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20060423	Binding Agent 1064
Nischarin 7 Target ID: Q9Y2I1\|\|\|Q9UFW3 Gene ID: 11188.0 Gene Symbol: NISCH Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12652347	Binding Agent 1064

Conditions

Condition	Modality	Highest Phase	Product
Depression 235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564606	Primary	Not Provided 504	Unknown Approved Use Unknown
Cancer 592 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24040395 https://www.ncbi.nlm.nih.gov/pubmed/25152370	Primary	Basic research	Unknown Approved Use Unknown
Obsessive-compulsive disorder 28 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6342562	Primary	Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Possible development of the serotonin syndrome in man.	1982 Jul	7091416
Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients.	1982 May	7092487
Brain monoamine oxidase in suckling rabbits treated with organophosphorus compound. I. Acute intoxication.	1984 Mar-Apr	6443171
Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia.	1984 Sep	6493360
Inhibition of monoamine oxidase activity by phenylpropanolamine, an anorectic agent.	1986 Feb	3961266
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.	1987 Sep	3670563
Dissociation of norepinephrine turnover from alpha-2 responses after clorgiline.	1988 Jan	2826065
Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).	1998	9564606
Effects of elevated serotonin levels on patterns of GAP-43 expression during barrel development in rat somatosensory cortex.	2002 Dec 15	12480131
Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex.	2003 Jul 11	12818349
Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening.	2011	22028826
Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.	2011 Dec 22	22023459
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.	2011 Jul 28	21696156
Synthesis of three novel fluorine-18 labeled analogues of L-deprenyl for positron emission tomography (PET) studies of monoamine oxidase B (MAO-B).	2011 Oct 27	21923198
Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.	2011 Oct 27	21923181
The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.	2012 Mar	22203607
Piperine potentiates the antidepressant-like effect of trans-resveratrol: involvement of monoaminergic system.	2013 Dec	23943324
A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency.	2013 Feb 5	23386436
Acute effects of resveratrol to enhance cocaine-induced dopamine neurotransmission in the striatum.	2013 May 10	23499958
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.	2015 Jan 5	25455453
Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.	2015 Mar 25	25656918

Patents

Sample Use Guides

In Vivo Use Guide

Patients suffering depression were administered 30 mg/day of Clorgyline for three or more weeks. However, this regime produced negligible changes in trace amine excretion including, phenylethylamine, para-tyramine, and meta-tyramine.

Route of Administration: Unknown

In Vitro Use Guide

T24, HCT116, and HL60 cells were incubated overnight and treated with 1 micro-, 0.3 µM or 0.1 µM of 5-Aza-CdR, respectively for 24 hours. After removal of 5-Aza-CdR, cells were treated with 10 µM clorgyline every day for 21 days. Multiple doses of clorgyline were tested: 1 µM, 10 µM, and 100 µM. Clorgyline was found to impair cell growth in a dose-dependent manner and the optimal dose was identified as 10 microM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:18:10 GMT 2023` Edited by `admin` on `Fri Dec 15 16:18:10 GMT 2023`
Record UNII	LYJ16FZU9Q
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLORGILINE

Official Name

English

CLORGYLINE

Common Name

English

N-(3-(2,4-DICHLOROPHENOXY)PROPYL)-N-METHYL-2-PROPYNYLAMINE

Systematic Name

English

M&B-9302

Code

English

M&B 9302

Code

English

clorgiline [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C667